A human study for evaluating effectiveness and safety of Theracurmin CR-033P on antioxidant capacity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0003322

Enrollment

Registered

2018-11-08

Start date

2018-10-10

Completion date

Unknown

Last updated

2021-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Visit 1(week -2), subject who voluntarily signs on the written informed consent is reviewed according to inclusion-exclusion criteria. After two-week run-in period, selected subje

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Subject who voluntarily agree to participate and signs informed consent form 2) Men and women aged 20 to under 65. 3) fulfill the current workout habits or diet habits during the study.

Exclusion criteria

Exclusion criteria: 1) Impossible to performa treadmill activity 2) Continuous intensive workout (more than 1.5 hours a week) within 3 months from the first visit 3) Chronic smoker (= 10 cigarettes / day) 4) Intake more than 420 g of pure alcohol a week (Soju 7bottles/week, 1bottle/day) or an alcoholic 5) Recommended Food Score > 36 6) BMI<18.5 or BMI=30 7) Controlling body weight or have changed of body weight more than 4kg within 4 weeks before the first visit 8) Comply the following categories - Have following diseases or taking relevant medicines: Systemic infection, severe cardiovascular disease (hypertension, stroke), digestive system disease, kidney disease, thyroid disease, autoimmune disease, malignant tumor, multisystem failure, inflammatory bowel disease, uncontrolled meantal illness, HIV - Those who have received organ transplants and bone marrow transplants - Those who taking steroids, antibiotics, and anti-inflammatory drugs (NSAIDs) continuously within 1 month before the first visit - Therapeutic uses of coumadin, aspirin, or other medications that influence hemostasis within three weeks of the first visit. 9) Continuous consumption of health functional food(Coenzyme Q10,antioxidantsmultivitamin etc), and medicinal herbs within 1 months before the first visit 10) Donated blood within 1 month before the first visit 11) Known hypersensitivity to study product or any ingredient in study product 12) Pregnant or lactating women 13) Participation in other human study within 1 month before the first visit 14) Any condition that the principal investigator believes may put the subjects at under risk

Design outcomes

Primary

Measure	Time frame
antioxidant enzyme activity (Superoxide dismutase, catalase activity etc), oxidative stress marker (Thiobarbituric acid reactive substances, 8-hydroxydeoxyguanosine etc)	—

Secondary

Measure	Time frame
Inflammation markers (tumor necrosis factor-a, interleukin-6 etc)	—

Countries

Korea, Republic of

Contacts

Public ContactHeegeun Park

Chungnam National University

Outcome results